ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 06/19/2012

ClinicalTrials.gov ID: NCT00949975

Study Identification

Unique Protocol ID:	D0520C00012
Brief Title:	A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
Official Title:	A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
Secondary IDs:	

Study Status

Record Verification:	June 2012
Overall Status:	Completed
Study Start:	July 2009
Primary Completion:	August 2010 [Actual]
Study Completion:	August 2010 [Actual]

Sponsor/Collaborators

Sponsor:	AstraZeneca
Responsible Party:	Sponsor
Collaborators:	

Oversight

FDA Regulated?:	Yes
Applicable Trial?:	Section 801 Clinical Trial? Yes Delayed Posting? No
IND/IDE Protocol?:	Yes
IND/IDE Information:	Grantor: CDER IND/IDE Number: 101.534 Serial Number: 014 Has Expanded Access? No
Review Board:	Approval Status: Approved Approval Number: 43/KBL/OIL/2009 Board Name: Komisja Bioetycznaprzy Okregowej Izbie Lekarskiej_ Krakowie Board Affiliation: Komisja Bioetycznaprzy Okregowej Izbie Lekarskiej_ Krakowie Phone: 0126191712 Email: a.krawczyk@hipokrates.org
Data Monitoring?:	Yes
Plan to Share Data?:	
Oversight Authorities:	Australia: Department of Health and Ageing Therapeutic Goods Administration Canada: Health Canada Germany: Federal Institute for Drugs and Medical Devices Japan: Ministry of Health, Labor and Welfare Philippines: Bureau of Food and Drugs Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Russia: Ministry of Health of the Russian Federation Slovakia: State Institute for Drug Control South Korea: Korea Food and Drug Administration (KFDA) Taiwan: Department of Health Ukraine: State Pharmacological Center - Ministry of Health United States: Food and Drug Administration

Study Description

Brief Summary:	The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.
Detailed Description:	

Conditions

Conditions:	Chronic Obstructive Pulmonary Disease
Keywords:	Chronic Obstructive Pulmonary Lung Respiratory disease Efficacy Safety and tolerability Placebo-controlled Pharmacokinetics COPD

Study Design

Study Type:	Interventional
Primary Purpose:	Basic Science
Study Phase:	Phase 2
Intervention Model:	Parallel Assignment
Number of Arms:	4
Masking:	Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Allocation:	Randomized
Endpoint Classification:	Efficacy Study
Enrollment:	838 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Active Comparator: 1 AZD9668 active treatment	Drug: AZD9668 2 x 30 mg oral tablets twice daily (bid) for 12 weeks
Active Comparator: 2 AZD9668 active treatment	Drug: AZD9668 2 x 10 mg oral tablets twice daily (bid) for 12 weeks
Active Comparator: 3 AZD9668 active treatment	Drug: AZD9668 2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
Placebo Comparator: 4 AZD9668 placebo treatment	Drug: AZD9668 Placebo 2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age: 40 Years

Maximum Age: 80 Years

Gender: Both

Accepts Healthy Volunteers?: No

Criteria: Inclusion Criteria:

- Diagnosis of COPD with symptoms over 1 year
- Smokers or ex-smokers
- Males or post-menopausal females between 40 and 80 years old
- Able to use electronic devices

Exclusion Criteria:

- Past history or current evidence of clinically significant heart disease
- Current diagnosis of asthma
- Patients who require long term oxygen therapy
- Treatment with antibiotics within 4 weeks of study visit 1b

Contacts/Locations

Study Officials: Claus Volgemeier, Dr.
Study Principal Investigator
Director der Klinik fur Innere Medizin mit Schwerpunkt Pneumologie-Universitatsklinikum GieBen und Marburg, D-35043 Marburg, Germany

Locations: Australia, South Australia
Research Site
Adelaide, South Australia, Australia

Australia, Queensland
Research Site
Carina Heights, Queensland, Australia

Australia, New South Wales
Research Site
Concord, New South Wales, Australia

Australia, South Australia
Research Site
Daw Park, South Australia, Australia

Australia, New South Wales
Research Site
Glebe, New South Wales, Australia

Research Site
Kogarah, New South Wales, Australia

Australia, Western Australia
Research Site
Nedlands, Western Australia, Australia

Australia, Victoria
Research Site
Parkville, Victoria, Australia

Canada, Nova Scotia
Research Site
Antigonish, Nova Scotia, Canada

Canada, Alberta
Research Site
Edmonton, Alberta, Canada

Canada, Ontario
Research Site
Grimsby, Ontario, Canada

Research Site
Hamilton, Ontario, Canada

Research Site
Kingston, Ontario, Canada

Canada, Quebec
Research Site
La Malbaie, Quebec, Canada

Research Site
Mirabel, Quebec, Canada

Canada, Ontario
Research Site

Mississauga, Ontario, Canada

Canada, Newfoundland and Labrador
Research Site
Mount Pearl, Newfoundland and Labrador, Canada

Canada, Quebec
Research Site
Quebec, Quebec, Canada

Research Site
Saint-leonard, Quebec, Canada

Canada, Saskatchewan
Research Site
Saskatoon, Saskatchewan, Canada

Canada, Ontario
Research Site
Toronto, Ontario, Canada

Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada

Germany
Research Site
Berlin, Germany

Research Site
Fulda, Germany

Research Site
Hannover, Germany

Research Site
Leipzig, Germany

Research Site
Marburg, Germany

Japan
Research Site
Asahikawa, Hokkaido, Japan

Research Site

Bunkyo, Japan

Research Site
Chuo, Tokyo, Japan

Research Site
Fukuoka, Fukuoka, Japan

Research Site
Himeji, Hyogo, Japan

Research Site
Hiroshima, Hiroshima, Japan

Research Site
Kagoshima, Kagoshima, Japan

Research Site
Kawasaki, Kanagawa, Japan

Research Site
Kishiwada, Osaka, Japan

Research Site
Kita-ku, Sakai, Osaka, Japan

Research Site
Kochi, Kochi, Japan

Research Site
Matsue, Shimane, Japan

Research Site
Matsumoto, Nagano, Japan

Research Site
Nakano-ku, Tokyo, Japan

Research Site
Nihonmatsu, Fukushima, Japan

Research Site
Noda, Chiba, Japan

Research Site
Saeki, Oita, Japan

Research Site
Sapporo, Hokkaido, Japan

Research Site
Seto, Aichi, Japan

Research Site
Tanabe, Wakayama, Japan

Research Site
Touon, Ehime, Japan

Research Site
Ukyo-ku, Kyoto, Kyoto, Japan

Research Site
Yokohama, Kanagawa, Japan

Research Site
Yukuhashi, Fukuoka, Japan

Philippines
Research Site
Iloilo City, Philippines

Research Site
Lipa City, Batangas, Philippines

Research Site
Quezon City, Philippines

Poland
Research Site
Bydgoszcz, Poland

Research Site
Checiny, Poland

Research Site
Krakow, Poland

Research Site
Ostrow Wielkopolski, Poland

Research Site
Poznan, Poland

Research Site
Proszowice, Poland

Research Site
Tczew, Poland

Research Site
Wroclaw, Poland

Research Site
Zawadzkie, Poland

Korea, Republic of
Research Site
Anyang, Korea, Republic of

Research Site
Bucheon, Korea, Republic of

Research Site
Daegu, Korea, Republic of

Research Site
Seoul, Korea, Republic of

Research Site
Uijeongbu, Gyeonggi-do, Korea, Republic of

Research Site
Wonju, Kangwon-do, Korea, Republic of

Russian Federation
Research Site
Barnaul, Russia, Russian Federation

Research Site
Ekaterinburg, Russia, Russian Federation

Research Site
Kazan, Russia, Russian Federation

Research Site
Moscow, Russia, Russian Federation

Research Site
Novosibirsk, Russia, Russian Federation

Research Site
St.petersburg, Russia, Russian Federation

Slovakia
Research Site
Bardejov, Slovakia

Research Site
Bojnice, Slovakia

Research Site
Bratislava, Slovakia

Research Site
Kosice, Slovakia

Research Site
Nove Mesto Nad Vahom, Slovakia

Research Site
Nove Zamky, Slovakia

Research Site
Poprad, Slovakia

Research Site
Presov, Slovakia

Research Site
Trnava, Slovakia

Research Site
Zilina, Slovakia

Research Site
Zvolen, Slovakia

Taiwan
Research Site
Kaohsiung, Taiwan

Research Site
Keelung, Taiwan

Research Site
Taichung, Taiwan

Research Site
Taipei, Taiwan

Research Site
Tao-yuan, Taiwan

Ukraine
Research Site
Dnipropetrovsk, Ukraine

Research Site
Ivano-frankivsk, Ivano-frankivsk, Ukraine

Research Site
Kharkiv, Ukraine

Research Site
Kyiv, Ukraine

Research Site
Lugansk, Ukraine, Ukraine

United States, Texas
Research Site
Boerne, Texas, United States

United States, Iowa
Research Site
Council Bluffs, Iowa, United States

United States, California
Research Site
Fullerton, California, United States

United States, South Carolina
Research Site
Gaffney, South Carolina, United States

Research Site
Greenville, South Carolina, United States

United States, North Carolina
Research Site
Hickory, North Carolina, United States

United States, Pennsylvania

Research Site
Jefferson Hills, Pennsylvania, United States

United States, South Carolina
Research Site
Spartanburg, South Carolina, United States

United States, Indiana
Research Site
Valparaiso, Indiana, United States

References

Citations:

Links:

Study Data/Documents:

Study Results

Participant Flow

Recruitment Details	First patient enrolled 13 July 2009. Last patient completed 05 August 2010. Study conducted at 138 centres in 12 countries (Australia, Canada, Germany, Japan, Korea, Philippines, Poland, Russia, Slovakia, Taiwan, Ukraine and US)
Pre-Assignment Details	Patients were stabilised on maintenance therapy (tiotropium, 18 micrograms od) during a 2-week run-in period before randomisation.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Overall Study

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Started	212	206	202	218
Completed	185	177	183	190
Not Completed	27	29	19	28
Voluntary discontinuation	6	5	3	6
Adverse Event	11	11	10	10
Safety reason	0	1	0	0
Study-specific criteria	0	1	1	0
Incorrect enrolment	5	10	4	7
Severe non-compliance	3	1	0	2
Lost to Follow-up	1	0	1	3
Other	1	0	0	0

Baseline Characteristics

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Baseline Measures

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo	Total
Number of Participants	212	206	202	218	838
Age, Continuous [units: Years] Mean (Full Range)	62 (42 to 80)	63 (42 to 79)	61 (40 to 79)	62 (41 to 80)	62 (40 to 80)
Gender, Male/Female [units: Participants]					
Female	46	47	53	53	199

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo	Total
Male	166	159	149	165	639

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Baseline Pre-bronchodilator FEV1 (L)
Measure Description	Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic
Time Frame	Day 1
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	209	199	201	216
Baseline Pre-bronchodilator FEV1 (L) [units: L] Mean (Standard Deviation)	1.51 (0.471)	1.47 (0.468)	1.50 (0.512)	1.51 (0.467)

2. Primary Outcome Measure:

Measure Title	End-value Pre-bronchodilator FEV1 (L)

Measure Description	End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)
Time Frame	Measured at clinic visits: 1, 4, 8 and 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	209	199	201	216
End-value Pre-bronchodilator FEV1 (L) [units: L] Least Squares Mean (Standard Error)	1.51 (0.018)	1.47 (0.018)	1.46 (0.018)	1.47 (0.018)

3. Secondary Outcome Measure:

Measure Title	Post-bronchodilator FEV1 (L) - Baseline
Measure Description	Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic
Time Frame	Day 1
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	207	199	201	215
Post-bronchodilator FEV1 (L) - Baseline [units: L] Mean (Standard Deviation)	1.68 (0.501)	1.64 (0.472)	1.65 (0.516)	1.69 (0.471)

4. Secondary Outcome Measure:

Measure Title	Post-bronchodilator FEV1 (L) - End-value
Measure Description	End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)
Time Frame	Measured at clinic visits: 1, 4, 8 and 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	207	199	201	215
Post-bronchodilator FEV1 (L) - End-value [units: L] Least Squares Mean (Standard Error)	1.66 (0.017)	1.63 (0.017)	1.63 (0.017)	1.62 (0.017)

5. Secondary Outcome Measure:

Measure Title	Pre-bronchodilator FVC (L) - Baseline
Measure Description	Forced Vital Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic
Time Frame	Day 1
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	209	199	201	216
Pre-bronchodilator FVC (L) - Baseline [units: L] Mean (Standard Deviation)	3.08 (0.850)	3.01 (0.739)	3.06 (0.856)	3.04 (0.754)

6. Secondary Outcome Measure:

Measure Title	Pre-bronchodilator FVC (L) - End-value
Measure Description	End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)
Time Frame	Measured at clinic visits: 1, 4, 8 and 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	209	199	201	216
Pre-bronchodilator FVC (L) - End-value [units: L] Least Squares Mean (Standard Error)	3.08 (0.026)	3.05 (0.026)	3.02 (0.026)	3.02 (0.025)

7. Secondary Outcome Measure:

Measure Title	Post-bronchodilator FVC (L) - Baseline
Measure Description	Forced Vital Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic
Time Frame	Day 1
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	207	199	201	215
Post-bronchodilator FVC (L) - Baseline [units: L] Mean (Standard Deviation)	3.30 (0.914)	3.24 (0.723)	3.24 (0.885)	3.27 (0.781)

8. Secondary Outcome Measure:

Measure Title	Post-bronchodilator FVC (L) - End-value
Measure Description	End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)
Time Frame	Measured at clinic visits: 1, 4, 8 and 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks

	Description
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	207	199	201	215
Post-bronchodilator FVC (L) - End-value [units: L] Least Squares Mean (Standard Error)	3.28 (0.023)	3.26 (0.024)	3.24 (0.024)	3.22 (0.023)

9. Secondary Outcome Measure:

Measure Title	Pre-bronchodilator IC (L) - Baseline
Measure Description	Inspiratory Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic
Time Frame	Day 1
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	209	199	200	216
Pre-bronchodilator IC (L) - Baseline	2.22 (0.680)	2.14 (0.563)	2.15 (0.662)	2.17 (0.574)

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
[units: L] Mean (Standard Deviation)				

10. Secondary Outcome Measure:

Measure Title	Pre-bronchodilator IC (L) - End-value
Measure Description	End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)
Time Frame	Measured at clinic visits: 1, 4, 8 and 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	209	199	200	216
Pre-bronchodilator IC (L) - End-value [units: L] Least Squares Mean (Standard Error)	2.15 (0.027)	2.15 (0.028)	2.16 (0.027)	2.15 (0.026)

11. Secondary Outcome Measure:

Measure Title	Post-bronchodilator IC (L) - Baseline

Measure Description	Inspiratory Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic
Time Frame	Day 1
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	206	199	201	214
Post-bronchodilator IC (L) - Baseline [units: L] Mean (Standard Deviation)	2.37 (0.709)	2.30 (0.601)	2.28 (0.677)	2.32 (0.628)

12. Secondary Outcome Measure:

Measure Title	Post-bronchodilator IC (L) - End-value
Measure Description	End of treatment value - week 12 for completers, otherwise Last Observation Carried forward (LOCF)
Time Frame	Measured at clinic visits: 1, 4, 8 and 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	206	199	201	214
Post-bronchodilator IC (L) - End-value [units: L] Least Squares Mean (Standard Error)	2.29 (0.025)	2.30 (0.025)	2.31 (0.025)	2.30 (0.025)

13. Secondary Outcome Measure:

Measure Title	PEF - Baseline Measured by Patient at Home (L/Min) in the Morning
Measure Description	Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning.Baseline is the mean of last 10 days of data before start of treatment
Time Frame	Baseline
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	210	205	202	217
PEF - Baseline Measured by Patient at Home (L/Min) in the Morning [units: L/min] Mean (Standard Deviation)	222.33 (83.177)	219.86 (90.395)	216.99 (91.299)	221.79 (89.005)

14. Secondary Outcome Measure:

Measure Title	PEF - End-value Measured by Patient at Home (L/Min) in the Morning
Measure Description	Peak Expiratory Flow (L/min)
Time Frame	Last 6 weeks on treatment
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	210	205	202	217
PEF - End-value Measured by Patient at Home (L/Min) in the Morning [units: L/min] Least Squares Mean (Standard Error)	214.30 (2.899)	214.55 (2.920)	212.35 (2.944)	220.47 (2.840)

15. Secondary Outcome Measure:

Measure Title	FEV1 - Baseline Measured by Patient at Home (L) in the Morning
Measure Description	Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning.Baseline is the mean of last 10 days of data before start of treatment
Time Frame	Baseline
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	210	205	202	217
FEV1 - Baseline Measured by Patient at Home (L) in the Morning [units: L] Mean (Standard Deviation)	1.40 (0.521)	1.34 (0.444)	1.36 (0.507)	1.38 (0.456)

16. Secondary Outcome Measure:

Measure Title	FEV1 - End-value Measured by Patient at Home (L) in the Morning
Measure Description	Forced Expiratory Volume in 1 second (L)
Time Frame	Last 6 weeks on treatment

Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	210	205	202	217
FEV1 - End-value Measured by Patient at Home (L) in the Morning [units: L] Least Squares Mean (Standard Error)	1.36 (0.018)	1.35 (0.018)	1.33 (0.018)	1.34 (0.018)

17. Secondary Outcome Measure:

Measure Title	EXACT - Baseline Total Score
Measure Description	EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status)scale). Baseline is the mean of last 10 days of data before start of treatment.
Time Frame	Baseline
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	207	205	200	214
EXACT - Baseline Total Score [units: Units on a scale] Mean (Standard Deviation)	43.17 (10.109)	42.38 (8.166)	42.37 (9.320)	40.95 (9.725)

18. Secondary Outcome Measure:

Measure Title	EXACT - End-value Total Score
Measure Description	EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status)scale). Last 6 weeks on treatment.
Time Frame	Measured daily in the evening for 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	207	205	200	214
EXACT - End-value Total Score [units: Units on a scale] Least Squares Mean (Standard Error)	39.97 (0.545)	39.72 (0.543)	40.59 (0.552)	39.71 (0.533)

19. Secondary Outcome Measure:

Measure Title	BCSS - Baseline Total Score
Measure Description	Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status)scale).Baseline is the mean of last 10 days of data before start of treatment
Time Frame	Baseline
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	210	205	202	217
BCSS - Baseline Total Score [units: Units on a scale] Mean (Standard Deviation)	4.85 (1.954)	4.66 (1.526)	4.79 (1.756)	4.48 (1.782)

20. Secondary Outcome Measure:

Measure Title	BCSS - End-value Total Score
Measure Description	Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0(best health status) to 12(worst possible status)scale). Last 6 weeks on treatment
Time Frame	Measured daily in the evening for 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	210	205	202	217
BCSS - End-value Total Score [units: Units on a scale] Least Squares Mean (Standard Error)	4.09 (0.098)	4.03 (0.099)	4.25 (0.100)	4.20 (0.096)

21. Secondary Outcome Measure:

Measure Title	Sputum Colour - Baseline
Measure Description	Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).
Time Frame	Baseline

Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	194	179	188	195
Sputum Colour - Baseline [units: Units on a scale] Mean (Standard Deviation)	2.15 (1.069)	2.34 (1.137)	2.13 (0.956)	2.16 (1.046)

22. Secondary Outcome Measure:

Measure Title	Sputum Colour - End Value
Measure Description	Sputum Colour as assessed by the Bronkotest scale, reported on a scale from 1 - clear (best health status) to 5 - dark green (worst possible health status).End of treatment week 12
Time Frame	Measured at clinic visits:1, 4, 8 and 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	194	179	188	195
Sputum Colour - End Value [units: Units on a scale] Least Squares Mean (Standard Error)	2.11 (0.062)	2.03 (0.065)	2.20 (0.063)	2.11 (0.062)

23. Secondary Outcome Measure:

Measure Title	Use of Reliever Medication
Measure Description	Daily average of number of inhalations of reliever medication
Time Frame	Last 6 weeks on treatment
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	209	204	202	215
Use of Reliever Medication [units: Inhalations] Least Squares Mean (Standard Error)	4.28 (0.173)	4.20 (0.175)	4.65 (0.175)	4.56 (0.170)

24. Secondary Outcome Measure:

Measure Title	Six-minute Walk Test - Distance Walked at Baseline (m)
Measure Description	
Time Frame	Day 1
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	194	184	191	205
Six-minute Walk Test - Distance Walked at Baseline (m) [units: m] Mean (Standard Deviation)	386.2 (125.22)	402.2 (111.98)	384.9 (115.50)	386.0 (132.48)

25. Secondary Outcome Measure:

Measure Title	Six-minute Walk Test - End-value Distance Walked (m)
Measure Description	distance walked on vist 6 - last on treatment clinic visit
Time Frame	Measured Day 1 and 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	194	184	191	205
Six-minute Walk Test - End-value Distance Walked (m) [units: m] Least Squares Mean (Standard Error)	396.7 (4.74)	397.8 (4.87)	411.2 (4.76)	409.5 (4.61)

26. Secondary Outcome Measure:

Measure Title	St George's Respiratory Questionnaire (COPD) - Overall Score at Baseline
Measure Description	St George’s Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).
Time Frame	Day 1
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	199	187	194	210
St George's Respiratory Questionnaire (COPD) - Overall Score at Baseline [units: Scores on a scale] Mean (Standard Deviation)	53.98 (18.276)	51.98 (18.207)	52.97 (18.234)	51.41 (18.849)

27. Secondary Outcome Measure:

Measure Title	St George's Respiratory Questionnaire (COPD) - End-value Overall Score
Measure Description	St George’s Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).questionaire assessed on vist 6 -(last on treatment clinic visit)
Time Frame	Measured Day 1 and 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	199	187	194	210
St George's Respiratory Questionnaire (COPD) - End-value Overall Score [units: Scores on a scale] Least Squares Mean (Standard Error)	49.50 (1.014)	49.49 (1.049)	47.93 (1.023)	46.35 (0.984)

28. Secondary Outcome Measure:

Measure Title	Exacerbations - Clinic Defined
Measure Description	Number of patients having a clinic defined disease exacerbation
Time Frame	Duration of the the treatment period - 12 weeks
Safety Issue?	No

Analysis Population Description

The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Measured Values

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
Number of Participants Analyzed	210	205	202	218
Exacerbations - Clinic Defined [units: Participants]	29	28	34	29

Reported Adverse Events

Time Frame	[Not specified]
Additional Description	[Not specified]

Reporting Groups

	Description
5 mg AZD9668	AZD9668 2x2.5 mg oral tablets twice daily (bid) for 12 weeks
20 mg AZD9668	AZD9668 2x10 mg oral tablets twice daily (bid) for 12 weeks
60 mg AZD9668	AZD9668 2x30 mg oral tablets twice daily (bid) for 12 weeks
Placebo	Matched Placebo Tablets

Serious Adverse Events

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	7/212 (3.3%)	14/206 (6.8%)	15/202 (7.43%)	9/218 (4.13%)
Cardiac disorders				
ACUTE MYOCARDIAL INFARCTION [A] †	1/212 (0.47%)	0/206 (0%)	0/202 (0%)	0/218 (0%)
ANGINA PECTORIS [A] †	1/212 (0.47%)	0/206 (0%)	0/202 (0%)	1/218 (0.46%)
MYOCARDIAL INFARCTION [A] †	1/212 (0.47%)	0/206 (0%)	0/202 (0%)	0/218 (0%)
Gastrointestinal disorders				
ABDOMINAL PAIN [A] †	0/212 (0%)	0/206 (0%)	0/202 (0%)	1/218 (0.46%)

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
GASTROINTESTINAL HAEMORRHAGE [A] †	0/212 (0%)	1/206 (0.49%)	0/202 (0%)	0/218 (0%)
General disorders				
GASTROINTESTINAL ULCER HAEMORRHAGE [A] †	0/212 (0%)	0/206 (0%)	0/202 (0%)	1/218 (0.46%)
Hepatobiliary disorders				
CHOLECYSTITIS [A] †	0/212 (0%)	0/206 (0%)	1/202 (0.5%)	0/218 (0%)
Infections and infestations				
ACUTE SINUSITIS [A] †	0/212 (0%)	0/206 (0%)	1/202 (0.5%)	0/218 (0%)
LOBAR PNEUMONIA [A] †	0/212 (0%)	0/206 (0%)	0/202 (0%)	1/218 (0.46%)
PNEUMONIA [A] †	0/212 (0%)	2/206 (0.97%)	0/202 (0%)	0/218 (0%)
PNEUMONIA BACTERIAL [A] †	0/212 (0%)	1/206 (0.49%)	0/202 (0%)	0/218 (0%)
SEPSIS [A] †	0/212 (0%)	1/206 (0.49%)	0/202 (0%)	0/218 (0%)
Injury, poisoning and procedural complications				
HUMERUS FRACTURE [A] †	0/212 (0%)	0/206 (0%)	0/202 (0%)	1/218 (0.46%)
UPPER LIMB FRACTURE [A] †	0/212 (0%)	0/206 (0%)	1/202 (0.5%)	0/218 (0%)
Investigations				
ALANINE AMINOTRANSFERASE INCREASED [A] †	1/212 (0.47%)	0/206 (0%)	0/202 (0%)	0/218 (0%)
ASPARTATE AMINOTRANSFERASE INCREASED [A] †	1/212 (0.47%)	0/206 (0%)	0/202 (0%)	0/218 (0%)
BLOOD CREATININE INCREASED [A] †	0/212 (0%)	0/206 (0%)	1/202 (0.5%)	0/218 (0%)
BLOOD UREA INCREASED [A] †	0/212 (0%)	0/206 (0%)	1/202 (0.5%)	0/218 (0%)
ELECTROCARDIOGRAM T WAVE INVERSION [A] †	0/212 (0%)	1/206 (0.49%)	0/202 (0%)	0/218 (0%)

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
GAMMA-GLUTAMYLTRANSFERASE INCREASED [A] †	1/212 (0.47%)	0/206 (0%)	0/202 (0%)	0/218 (0%)
LIVER FUNCTION TEST ABNORMAL [A] †	0/212 (0%)	0/206 (0%)	1/202 (0.5%)	0/218 (0%)
Metabolism and nutrition disorders				
DIABETES MELLITUS [A] †	0/212 (0%)	1/206 (0.49%)	0/202 (0%)	0/218 (0%)
Musculoskeletal and connective tissue disorders				
INTERVERTEBRAL DISC PROTRUSION [A] †	0/212 (0%)	0/206 (0%)	1/202 (0.5%)	0/218 (0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)				
BILE DUCT CANCER [A] †	1/212 (0.47%)	0/206 (0%)	0/202 (0%)	0/218 (0%)
COLON CANCER [A] †	0/212 (0%)	1/206 (0.49%)	0/202 (0%)	0/218 (0%)
PROSTATE CANCER [A] †	0/212 (0%)	1/206 (0.49%)	0/202 (0%)	0/218 (0%)
SQUAMOUS CELL CARCINOMA [A] †	0/212 (0%)	0/206 (0%)	1/202 (0.5%)	0/218 (0%)
Nervous system disorders				
CONVULSION [A] †	0/212 (0%)	0/206 (0%)	1/202 (0.5%)	0/218 (0%)
TRANSIENT ISCHAEMIC ATTACK [A] †	0/212 (0%)	1/206 (0.49%)	0/202 (0%)	0/218 (0%)
Renal and urinary disorders				
NEPHROLITHIASIS [A] †	0/212 (0%)	1/206 (0.49%)	0/202 (0%)	0/218 (0%)
URETERIC OBSTRUCTION [A] †	0/212 (0%)	1/206 (0.49%)	0/202 (0%)	0/218 (0%)
Respiratory, thoracic and mediastinal disorders				
'RESPIRATORY FAILURE [A] †	0/212 (0%)	0/206 (0%)	1/202 (0.5%)	0/218 (0%)
CHRONIC OBSTRUCTIVE PULMONARY DISEASE [A] †	1/212 (0.47%)	8/206 (3.88%)	7/202 (3.47%)	4/218 (1.83%)
DYSPNOEA [A] †	0/212 (0%)	0/206 (0%)	0/202 (0%)	1/218 (0.46%)

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
HAEMOPTYSIS [A] †	1/212 (0.47%)	0/206 (0%)	1/202 (0.5%)	0/218 (0%)
PULMONARY EMBOLISM [A] †	0/212 (0%)	0/206 (0%)	0/202 (0%)	1/218 (0.46%)
Vascular disorders				
THROMBOSIS [A] †	0/212 (0%)	0/206 (0%)	0/202 (0%)	1/218 (0.46%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 13.0

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	5 mg AZD9668	20 mg AZD9668	60 mg AZD9668	Placebo
	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)	Affected/At Risk (%)
Total	17/212 (8.02%)	14/206 (6.8%)	13/202 (6.44%)	24/218 (11.01%)
Infections and infestations				
NASOPHARYNGITIS [A] †	15/212 (7.08%)	9/206 (4.37%)	9/202 (4.46%)	13/218 (5.96%)
Nervous system disorders				
HEADACHE [A] †	3/212 (1.42%)	5/206 (2.43%)	5/202 (2.48%)	11/218 (5.05%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 13.0

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Official Title: Gerard Lynch

Organization: AstraZeneca

Phone:

Email: aztrial_results_posting@astrazeneca.com